Healthcare
ByCan Attovia Therapeutics’ Nasdaq IPO Signal a Broader Biotech Funding Revival Backed by Goldman Sachs and Deep Track Capital?
Key Highlights A Landmark Filing Reflecting Renewed Confidence in Biopharma Innovation Attovia Therapeutics’ decision to file for a…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Sanofi’s Twin Lawsuits Against Pfizer and Moderna Reopen the Bill for $140 Billion-Plus in COVID Vaccine Revenue?
Key Highlights Two Companies, One Shared Technology Dispute Sanofi’s complaints, filed as Translate Bio Inc v. Pfizer Inc…
Pfizer’s $10 Billion Innovent Alliance: Is China Now the Epicenter of Next-Gen Cancer Drug Discovery?
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
